Table 3.

Change from baseline in seated SBP/DBP

Placebo-controlled studies
	Placebo	Eplerenone 50 mg daily	Eplerenone 100 mg daily	Eplerenone 50 mg vs placebo	Eplerenone 100 mg vs placebo
Mean change from baseline in BPa (SBP/DBP)	−4.98/−5.67	−12.53/−9.72	−13.73/−9.96	−7.55/−4.05	−8.75/−4.30
95% CI for SBP	−6.03, −3.93	−13.73, −11.33	−15.22, −12.24	−9.14, −5.96	−10.57, −6.93
95% CI for DBP	−6.30, −5.03	−10.44, −8.99	−10.86, −9.06	−5.01, −3.09	−5.39, −3.20
P-value				<0.0001/<0.0001	<0.0001/<0.0001
Active-controlled studies
	Active treatment	Eplerenone 50 mg daily	Eplerenone 100 mg daily	Eplerenone 50 mg vs active	Eplerenone 100 mg vs active
Mean change from baseline in BPa	−13.28/−9.31	−16.53/−11.21	−17.58/−10.77	−3.25/−1.90	−4.30/−1.46
95% CI for SBP	−14.29, −12.27	−18.27, −14.79	−19.58, −15.58	−5.25, −1.25	−6.56, −2.03
95% CI for DBP	−9.91, −8.71	−12.25, −10.17	−11.96, −9.59	−3.09, −0.71	−2.81, −0.12
P-value				0.0015/0.0018	0.0002/0.0328

Note:

^aPooled least-square means and 95% CI based on a meta-analysis fixed-effects model with factors for study, treatment group, and baseline covariate.

Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.